Ductal Carcinoma In Situ Tied to Threefold Higher Risk for Death

Risk for dying from breast cancer remains elevated 15 years after initial diagnosis
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Family Medicine, Geriatrics, Gynecology, Internal Medicine, Oncology, Journal, Source Type: news

Related Links:

DiscussionICG administration timing during the angiography phase compared with the EPR phase improved TBR and diagnostic accuracy. Future work will focus on image pattern analysis and adaptation of the camera system to targeting fluorophores specific to breast cancer.
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
Pract Radiat Oncol. 2021 Aug 30:S1879-8500(21)00225-3. doi: 10.1016/j.prro.2021.08.009. Online ahead of print.ABSTRACTPURPOSE/OBJECTIVE(S): Randomized data support accelerated partial breast irradiation (APBI) for early-stage breast cancer with variable techniques and cosmesis outcomes. We have treated patients with 5-fraction prone external beam APBI for over a decade and herein report acute and late outcomes.MATERIALS/METHODS: Patients receiving APBI 600cGy x 5 between 2010-2019 were included. APBI was primarily delivered prone, with opposed tangents targeting the tumor bed expanded by 1.5cm, (cropped 6mm from skin). Ips...
Source: Pain Physician - Category: Anesthesiology Authors: Source Type: research
ConclusionsHigh-risk screening might facilitate downstaging of detected breast tumor among BRCA1/2 carrier population.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
The three risk assessment tools now in use fall far short. Using the latest deep learning techniques, investigators are developing more personalized ways to locate women at high risk.John Halamka, M.D., president, Mayo Clinic Platform, and Paul Cerrato, senior research analyst and communications specialist, Mayo Clinic Platform, wrote this article.The promise of personalized medicine will eventually allow clinicians to offer individual patients more precise advice on prevention, early detection and treatment. Of course, the operative word iseventually.A closer examination of the screening tools available to detect breast c...
Source: Life as a Healthcare CIO - Category: Information Technology Source Type: blogs
CONCLUSIONS: It appeared that local recurrence-free survival is probably worse with PBI/APBI; however, the difference was small and nearly all women remain free of local recurrence. Overall survival is similar with PBI/APBI and WBRT, and we found little to no difference in other oncological outcomes. Some late effects (subcutaneous fibrosis) may be worse with PBI/APBI and its use is probably associated with worse cosmetic outcomes. The limitations of the data currently available mean that we cannot make definitive conclusions about the efficacy and safety or ways to deliver PBI/APBI. We await completion of ongoing trials.P...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Source Type: research
The incidence of ductal carcinoma in situ (DCIS) is increasing due to more widespread mammographic screening. DCIS, the earliest form of breast cancer, is non-invasive at the time of detection. If DCIS tissues...
Source: BMC Research Notes - Category: Research Authors: Tags: Data note Source Type: research
This article provides an overview of currently available molecular assays and testing modalities that have prognostic, predictive, and therapeutic value. These include multigene assays for invasive breast cancer (Oncotype DX, MammaPrint, Prosigna, and Breast Cancer Index) and ductal carcinoma in situ (Oncotype DX DCIS and DCISionRT) and companion tests to detect PIK3CA mutations and NTRK fusions.
Source: Journal of Molecular Diagnostics - Category: Pathology Authors: Tags: Review Source Type: research
This article provides an overview of currently available molecular assays and testing modalities that have prognostic, predictive, and therapeutic value. These include multi-gene assays for invasive breast cancer (Oncotype DX, MammaPrint, Prosigna, and Breast Cancer Index) and ductal carcinoma in situ (Oncotype DX DCIS and DCISionRT), and companion tests to detect PIK3CA mutations and NTRK fusions.
Source: Journal of Molecular Diagnostics - Category: Pathology Authors: Tags: Review Source Type: research
CONCLUSION: LCIS incidence increased, surgical treatment decreased. The low mortality risks support consideration of active surveillance. However, the increased IBC incidence suggests careful monitoring.PMID:34428722 | DOI:10.1016/j.breast.2021.07.020
Source: Breast - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: RT significantly reduced all and invasive IBR for good-risk DCIS with durable results at 15 years. These results are not an absolute indication for RT but rather should inform shared patient-physician treatment decisions about ipsilateral breast risk reduction in the long term following lumpectomy.PMID:34406870 | DOI:10.1200/JCO.21.01083
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Carcinoma in Situ | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | Geriatrics | Internal Medicine